IRD

Company Overview — What Does Opus Genetics, Inc. Do?

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan. Opus Genetics, Inc. (IRD) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO George Magrath and employs approximately 14 people. With a market capitalization of $334M, IRD is one of the notable companies in the Healthcare sector.

Opus Genetics, Inc. (IRD) Stock Rating — Reduce (April 2026)

As of April 2026, Opus Genetics, Inc. receives a Reduce rating with a composite score of 36.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IRD ranks #2,212 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Opus Genetics, Inc. ranks #257 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IRD Stock Price and 52-Week Range

Opus Genetics, Inc. (IRD) currently trades at $5.42. The stock lost $0.08 (1.5%) in the most recent trading session. The 52-week high for IRD is $5.30, which means the stock is currently trading 2.3% from its annual peak. The 52-week low is $0.65, putting the stock 733.8% above its annual trough. Recent trading volume was 870K shares, suggesting relatively thin trading activity.

Is IRD Overvalued or Undervalued? — Valuation Analysis

Opus Genetics, Inc. (IRD) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 22.81x, versus the sector average of 2.75x. The price-to-sales ratio is 24.66x, compared to 1.66x for the average Healthcare stock.

At current multiples, Opus Genetics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Opus Genetics, Inc. Profitability — ROE, Margins, and Quality Score

Opus Genetics, Inc. (IRD) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -264.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -80.8% versus the sector average of -33.1%.

On a margin basis, Opus Genetics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -253.3% (sector: -66.1%). Net profit margin stands at -301.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 176.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IRD Debt, Balance Sheet, and Financial Health

Opus Genetics, Inc. has a debt-to-equity ratio of 227.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 6.43x, indicating strong short-term liquidity. Total debt on the balance sheet is $1M. Cash and equivalents stand at $31M.

IRD has a beta of 0.76, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Opus Genetics, Inc. is 44/100, reflecting average volatility within the normal range for its sector.

Opus Genetics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Opus Genetics, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-41M. Gross margin was 100.0%. Operating income came in at $-35M.

In FY 2025, Opus Genetics, Inc. reported revenue of $14M and earnings per share (EPS) of $-0.80. Net income for the quarter was $-50M. Revenue grew 29.1% year-over-year compared to FY 2024. Operating income came in at $-39M.

In Q3 2025, Opus Genetics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-17M. Revenue grew -20.4% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, Opus Genetics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.12. Net income for the quarter was $-7M. Gross margin was 100.0%. Revenue grew 159.2% year-over-year compared to Q2 2024. Operating income came in at $-9M.

Over the past 8 quarters, Opus Genetics, Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $14M. Investors analyzing IRD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IRD Dividend Yield and Income Analysis

Opus Genetics, Inc. (IRD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IRD Momentum and Technical Analysis Profile

Opus Genetics, Inc. (IRD) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 38/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IRD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Opus Genetics, Inc. (IRD) ranks #257 out of 838 stocks based on the Blank Capital composite score. This places IRD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IRD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IRD vs S&P 500 (SPY) comparison to assess how Opus Genetics, Inc. stacks up against the broader market across all factor dimensions.

IRD Next Earnings Date

No upcoming earnings date has been announced for Opus Genetics, Inc. (IRD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IRD? — Investment Thesis Summary

The quantitative profile for Opus Genetics, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 78/100, suggesting the trend favors buyers.

In summary, Opus Genetics, Inc. (IRD) earns a Reduce rating with a composite score of 36.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IRD stock.

Related Resources for IRD Investors

Explore more research and tools: IRD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IRD head-to-head with peers: IRD vs AZN, IRD vs SLGL, IRD vs VMD.